The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Earnings drive big swings in European stocks ahead of Fed

Wed, 29th Jul 2020 09:50

(For a live blog on European stocks, type LIVE/ in an Eikon
news window)

* Investors await Fed, U.S. fiscal stimulus update

* Paris outperforms as Kering, Schneider earnings support

* Chemicals giant BASF slides as dividend under review
(Updates to market close)

By Sruthi Shankar

July 29 (Reuters) - Europe's main stocks benchmark closed
nearly flat on Wednesday, as investors waited to hear from the
U.S. Federal Reserve, but a flurry of earnings reports drove big
swings in individual stocks.

When the Fed concludes its monetary policy meeting later in
the day, investors are hoping that policymakers will reiterate
their accommodative stance to support financial markets as the
coronavirus pandemic takes its toll.

In a busy earnings day, the pan-European STOXX 600
closed down 0.1%, with healthcare and banks
dragging on the main index, while retailers jumped 1.4%.

Drugmaker GlaxoSmithKline fell 3.2% as it missed
second-quarter profit estimates after lower sales of its
existing vaccines, while lender Barclays dropped 6.1%
as it set aside a higher than expected 1.6 billion pounds ($2.1
billion) to cover a possible rise in loan losses due to the
pandemic.

The pair helped keep London's FTSE 100 nearly flat.

France's CAC 40 outperformed its continental peers
with a 0.6% rise after positive earnings updates from luxury
group Kering, electrical equipment group Schneider
Electric and consulting firm Capgemini.

"Markets have rallied aggressively, so what we're seeing is
companies coming with better numbers but not seeing an
additional uptick in markets," said Will James, deputy head of
European equities at Aberdeen Standard Investments.

"Companies that have managed earnings and sales, there have
been aggressive cost measures put in place."

Profits for STOXX 600 companies are expected to drop by a
record 59% in the second quarter, according to Refinitiv data.
But with much of the decline priced in, European stocks are on
course to end July with gains as investors bet on more stimulus.

Euro zone banks took a beating as Deutsche Bank
fell 2.5% after giving a slightly improved outlook
for the year, but chief executive Christian Sewing damped
speculation that the lender was eager to revive merger talks
with Commerzbank.

Spain's Santander slid 4.7% as it reported a record
net loss of 11.1 billion euros ($13 billion) in the second
quarter.

Chemicals giant BASF SE dropped 4.9% as it said
its dividend policy and the value of assets on its balance sheet
might be revised given uncertainty caused by the coronavirus
crisis.

UK retailer Next jumped 7.7% as it raised its profit
forecast after sales fell less than feared over the past three
months.
(Reporting by Sruthi Shankar in Bengaluru; Editing by Bernard
Orr and Uttaresh.V)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.